PT3556351T - Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos - Google Patents
Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambosInfo
- Publication number
- PT3556351T PT3556351T PT193860160T PT19386016T PT3556351T PT 3556351 T PT3556351 T PT 3556351T PT 193860160 T PT193860160 T PT 193860160T PT 19386016 T PT19386016 T PT 19386016T PT 3556351 T PT3556351 T PT 3556351T
- Authority
- PT
- Portugal
- Prior art keywords
- iron
- polymaltose
- vitamin
- blood
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20180100160A GR1009597B (el) | 2018-04-16 | 2018-04-16 | Φαρμακευτικο σκευασμα για την ενισχυση των επιπεδων σιδηρου στο αιμα, που περιεχει πολυμαλτοζικο σιδηρο (ιιι) και μια δραστικη ουσια επιλεγμενη απο πενταϋδρικο φυλλινικο ασβεστιο, βιταμινη c ή συνδυασμο των δυο, που ενισχυει την απορροφηση σιδηρου |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3556351T true PT3556351T (pt) | 2023-09-12 |
Family
ID=66102021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT193860160T PT3556351T (pt) | 2018-04-16 | 2019-03-22 | Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3556351B1 (pt) |
DK (1) | DK3556351T3 (pt) |
ES (1) | ES2956286T3 (pt) |
FI (1) | FI3556351T3 (pt) |
GR (1) | GR1009597B (pt) |
HR (1) | HRP20231108T1 (pt) |
HU (1) | HUE063948T2 (pt) |
LT (1) | LT3556351T (pt) |
MA (1) | MA49589B1 (pt) |
PL (1) | PL3556351T3 (pt) |
PT (1) | PT3556351T (pt) |
RS (1) | RS64559B1 (pt) |
SI (1) | SI3556351T1 (pt) |
SM (1) | SMT202300309T1 (pt) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931441A (en) * | 1988-11-09 | 1990-06-05 | Luitpold Pharmaceuticals, Inc. | Stabilized aqueous leucovorin calcium compositions |
IT1237509B (it) * | 1989-10-31 | 1993-06-08 | Magis Farmaceutici | Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche |
BRPI0617227A2 (pt) * | 2005-10-11 | 2011-07-19 | Bayer Consumer Care Ag | mistura de sais de ferro e cobre disfarçando gosto metálico |
EP1790356A1 (de) * | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
ITTO20120506A1 (it) | 2012-06-12 | 2013-12-13 | Inge Spa | Cappuccio per un flacone atto alla conservazione di sostanze da mantenersi separate fino alla loro applicazione. |
EP2997968A1 (en) | 2014-09-22 | 2016-03-23 | Ioulia Tseti | Iron (III) hydroxide complexes with activated glucose syrups and process for preparing same |
-
2018
- 2018-04-16 GR GR20180100160A patent/GR1009597B/el active IP Right Grant
-
2019
- 2019-03-22 SM SM20230309T patent/SMT202300309T1/it unknown
- 2019-03-22 PL PL19386016.0T patent/PL3556351T3/pl unknown
- 2019-03-22 HU HUE19386016A patent/HUE063948T2/hu unknown
- 2019-03-22 SI SI201930621T patent/SI3556351T1/sl unknown
- 2019-03-22 PT PT193860160T patent/PT3556351T/pt unknown
- 2019-03-22 HR HRP20231108TT patent/HRP20231108T1/hr unknown
- 2019-03-22 EP EP19386016.0A patent/EP3556351B1/en active Active
- 2019-03-22 MA MA49589A patent/MA49589B1/fr unknown
- 2019-03-22 RS RS20230778A patent/RS64559B1/sr unknown
- 2019-03-22 ES ES19386016T patent/ES2956286T3/es active Active
- 2019-03-22 DK DK19386016.0T patent/DK3556351T3/da active
- 2019-03-22 LT LTEP19386016.0T patent/LT3556351T/lt unknown
- 2019-03-22 FI FIEP19386016.0T patent/FI3556351T3/fi active
Also Published As
Publication number | Publication date |
---|---|
ES2956286T3 (es) | 2023-12-18 |
PL3556351T3 (pl) | 2023-11-27 |
MA49589A (fr) | 2020-05-20 |
HRP20231108T1 (hr) | 2023-12-22 |
HUE063948T2 (hu) | 2024-02-28 |
SI3556351T1 (sl) | 2024-02-29 |
FI3556351T3 (fi) | 2023-10-02 |
SMT202300309T1 (it) | 2023-11-13 |
GR1009597B (el) | 2019-09-16 |
RS64559B1 (sr) | 2023-10-31 |
DK3556351T3 (da) | 2023-09-18 |
EP3556351A1 (en) | 2019-10-23 |
LT3556351T (lt) | 2023-09-25 |
MA49589B1 (fr) | 2023-09-27 |
EP3556351B1 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
MY196631A (en) | Antibody Agents Specific for Human Cd19 and uses Thereof | |
PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
MX2020010607A (es) | Compuestos y metodos para inhibir el transporte de fosfato. | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
UA116793C2 (uk) | Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин | |
PH12021551302A1 (en) | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | |
MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
WO2015059463A3 (en) | Treatment of beta-catenin related diseases8 | |
MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
TR201004464A2 (tr) | Kemik erimesi için formülasyon. | |
PT3556351T (pt) | Composição farmacêutica para melhorar os níveis de ferro no sangue, compreendendo polimaltose de ferro (iii) e outra substância ativa adequada para absorçâo de ferro, selecionada entre folinato de cálcio penta-hidratado, vitamina c ou uma combinação de ambos | |
BR112019001130A2 (pt) | uso de lactama e composição farmacêutica | |
DE60019947D1 (de) | Vorbeugung von kolorektalkrebs | |
PH12019502290A1 (en) | Therapeutic agent for blood cancer | |
MX2017017177A (es) | Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona. | |
PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
GB2592457B (en) | Bad odor reduction by Mg complex in deodorant emulsion for aerosols, deodorant comprising the same and use of the deodorant | |
WO2019035602A3 (ko) | 혈액 내 gkn1 단백을 이용하는 위암 진단 | |
ATE444072T1 (de) | Prävention von epithelzellkarzinom | |
PH22014000055Y1 (en) | A composition for a vitamin supplement containing calcium, vitamin c and vitamin d3 for better absorption |